5-HT receptor agonist Valerenic Acid enhances the innate immunity signal and suppresses glioblastoma cell growth and invasion
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (12) , 2104-2115
Abstract
Glioblastoma multiform (GBM) continues to threaten people's lives due to the limited therapeutic strategies. As a new drug, Valerenic Acid suppresses the progression of GBM, however, the mechanism is largely unknown. Here, we found that Valerenic Acid can inhibit cell proliferation, migration and invasion of GBM cells by increasing innate immune signals such as enhancing ROS levels and activating the AMPK pathway. Inhibition of ROS by N-acetylcysteine (NAC) or attenuation of AMPK by Compound C could block Valerenic Acid-induced cell death. Additionally, the xenograft mouse model also confirmed that Valerenic Acid had anti-tumor effect. Together, our results provide compelling rational to develop Valerenic Acid as an anti-tumor agent against GBM patients.Keywords
This publication has 18 references indexed in Scilit:
- The design, synthesis, and anti-inflammatory evaluation of a drug-like library based on the natural product valerenic acidBioorganic & Medicinal Chemistry Letters, 2017
- Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011Journal of Neuro-Oncology, 2015
- Epidemiologic and Molecular Prognostic Review of GlioblastomaCancer Epidemiology, Biomarkers & Prevention, 2014
- Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institutionBMC Cancer, 2013
- Expression of Serotonin Receptors in Human Hepatocellular CancerClinical Cancer Research, 2012
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitroMolecular Brain Research, 2005
- Expression of Serotonin Receptors 2B and 4 in Human Prostate Cancer Tissue and Effects of Their Antagonists on Prostate Cancer Cell LinesEuropean Urology, 2005
- Regulation and measurement of oxidative stress in apoptosisJournal of Immunological Methods, 2002
- Role of reactive oxygen species (ROS) in apoptosis inductionApoptosis, 2000